(Non-)ST-elevation myocardial infarction and Multivessel coronary Artery disease: coronary Resistance guided multivessel Treatment.

• Conditions: coronary artery disease; coronary sclerosis; 10011082

• Registration Number: NL-OMON34491
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

Patients with a second and/or third coronary lesion in the presence of a successfully treated acute coronary occlusion of another coronary vessel are amendable for inclusion.

Exclusion Criteria

- Age under 18 and above 80 yrs.
- Cardiogenic shock
- Anatomical or anticipated problems for complete percutaneous coronary revascularization i.e. diffuse disease, chronic total occlusion.
- Prior or indication for coronary artery bypass grafting (CABG)
- Presence of a significant left main coronary artery stenosis (> 50% diameter stenosis)
- Renal impairment (e.g. serum creatinine level of more than 130 *mol/L)
-Unable to exercise
-Ventricular arrhythmias, i.e. sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), more than 48 hours after primary PCI
-Severe valvular heart disease requiring cardiac surgery within twelve months
-Serious known concomitant disease with a life expectancy of less than one year
-Factors making follow-up difficult (e.g. not fixed home or address, psychological instability, drugs or alcohol addiction, etc.).
-Current participation in another trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>A composite of cardiac death, acute myocardial infarction, recurrent<br /><br>revascularization guided by objective evidence of myocardial ischemia at 12<br /><br>months.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>A composite of all-cause death, myocardial infarction, stroke, severe vascular<br /><br>events, recurrent revascularization guided by objective evidence of myocardial<br /><br>ischemia at 12 months.</p><br>